GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Gross Margin %

Science 37 Holdings (Science 37 Holdings) Gross Margin % : 39.73% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Science 37 Holdings's Gross Profit for the three months ended in Sep. 2023 was $5.92 Mil. Science 37 Holdings's Revenue for the three months ended in Sep. 2023 was $14.89 Mil. Therefore, Science 37 Holdings's Gross Margin % for the quarter that ended in Sep. 2023 was 39.73%.


The historical rank and industry rank for Science 37 Holdings's Gross Margin % or its related term are showing as below:

SNCE' s Gross Margin % Range Over the Past 10 Years
Min: 22.62   Med: 22.62   Max: 29.74
Current: 29.74


During the past 3 years, the highest Gross Margin % of Science 37 Holdings was 29.74%. The lowest was 22.62%. And the median was 22.62%.

SNCE's Gross Margin % is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 41.61 vs SNCE: 29.74

Science 37 Holdings had a gross margin of 39.73% for the quarter that ended in Sep. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Science 37 Holdings was 0.00% per year.


Science 37 Holdings Gross Margin % Historical Data

The historical data trend for Science 37 Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Gross Margin % Chart

Science 37 Holdings Annual Data
Trend Jun20 Jun21 Dec22
Gross Margin %
- - 22.62

Science 37 Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.18 22.87 21.13 35.09 39.73

Competitive Comparison of Science 37 Holdings's Gross Margin %

For the Health Information Services subindustry, Science 37 Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Science 37 Holdings's Gross Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Science 37 Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Science 37 Holdings's Gross Margin % falls into.



Science 37 Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Science 37 Holdings's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=15.9 / 70.147
=(Revenue - Cost of Goods Sold) / Revenue
=(70.147 - 54.278) / 70.147
=22.62 %

Science 37 Holdings's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=5.9 / 14.887
=(Revenue - Cost of Goods Sold) / Revenue
=(14.887 - 8.972) / 14.887
=39.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Science 37 Holdings  (NAS:SNCE) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Science 37 Holdings had a gross margin of 39.73% for the quarter that ended in Sep. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Science 37 Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Science 37 Holdings (Science 37 Holdings) Business Description

Traded in Other Exchanges
N/A
Address
800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709
Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Executives
Troy Bryenton officer: Chief Technology Officer 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari officer: Chief Legal Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von director BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton officer: Chief Commercial Officer 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman officer: Chief Delivery Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman director, officer: Chief Executive Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar officer: Chief Medical Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon officer: Chief Commercial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B. director PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek officer: Chief Financial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc. 10 percent owner 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331